ARNA Financial Facts

Net loss per share allocable to common stockholders, diluted: 0.03
Research and development: 27.03M
See Full Income Statement

Accumulated other comprehensive income: 23.65M
Commitments and contingencies and subsequent events: 0
See Full Balance Sheet

Arena Pharmaceuticals, Inc. (ARNA) Earnings

  |   Expand Research on ARNA
Next EPS Date 11/3/14 EPS Growth Rate -50.0%
Average EPS % Beat Rate +35.2% Revenue Growth Rate +202.8%
Average % Move 1-Wk after EPS +3.3% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/3/14 Q314 N/A-$0.12 N/A N/A$10.9M N/A N/A N/A
8/1/14 Q214 $0.03-$0.11 +$0.14$12.8M$9.81M N/A Details
5/12/14 Q114 -$0.12-$0.10 -$0.02$6.8M$7.98M N/A Details
2/27/14 Q413 -$0.11-$0.11 $0.00$6.2M$7M N/A Details
11/7/13 Q313 -$0.08-$0.12 +$0.04$3.6M$5.3M N/A Details
8/1/13 Q213 $0.18$0.15 +$0.03$68.9M$57.3M N/A Details
5/2/13 Q113 $0.09$0.11 -$0.02N/A$50.36M N/A Details
3/4/13 Q412 -$0.10-$0.03 -$0.07$1.94M$21.94M N/A Details